title: Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.
abstract: A 44-year-old man was referred to our hospital with intermittent abdominal pain. Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction. A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall. Some mesenteric lymph nodes were swollen. Pathological examination was defined. We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses. Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2. Four cycles were performed every 6 mo and he remained CR. Rituximab may be effective as adjuvant therapy.
authors.affiliation: Molecular Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan. nomuken@sun.kpu-m.ac.jp
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nomura
authors.forename: Koichi
authors.initials: K
authors.lastname: Tomikashi
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Naohisa
authors.initials: N
authors.lastname: Yoshida
authors.forename: Takashi
authors.initials: T
authors.lastname: Okuda
authors.forename: Chohei
authors.initials: C
authors.lastname: Sakakura
authors.forename: Shoji
authors.initials: S
authors.lastname: Mitsufuji
authors.forename: Shigeo
authors.initials: S
authors.lastname: Horiike
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Yamagishi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D008297:Male; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab